WEST LAFAYETTE, Ind., April 1, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that the company has been added to the Russell 2000® Index, as part of Russell's quarterly IPO additions that took place on March 31, 2011, following the close of the market.
